Gilead slides 4% after coronavirus drug shows limited benefit in moderately ill patients
slipped 4% on Monday after a late-stage coronavirus drug trial showed that remdesivir had limited success treating moderately ill patients.
The company said that remdesivir helped patients in the trial with "moderate" disease recover more quickly when they took it for five days but it had limited benefits for patients who took it for 10 days. Gilead said patients in the group that received remdesivir for five days were 65% more likely to show signs of clinical improvement compared to those who got usual care, without receiving the drug.
Remdesivir has been tested as a treatment for patients with COVID-19. It has been authorized for emergency use by the US Food and Drug Administration and has been approved for use in Japan. While Monday's results affirm that remdesivir does have some success in treating COVID-19 it may raise questions how beneficial it will be overall.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
YouTube at 15: The inside story of YouTube's history - Business InsiderBusiness Insider is a fast-growing business site with deep financial, media, tech, and other industry verticals. Launched in 2007, the site is now the largest business news site on the web.
Read more »
Gilead says new data shows remdesivir coronavirus treatment helped moderately sick patients
Read more »
Russia Approves Flu Drug’s Use Against Covid-19Russia’s Ministry of Health on Saturday approved a flu drug for use in fighting coronavirus after officials said preliminary testing showed hospitalized patients who took the pills recovered more quickly.
Read more »
McConnell and Pelosi's next battle: How to help the 40 million unemployedThe divide over jobless benefits will dominate the fight over a new coronavirus aid package.
Read more »
‘The next patient could be me’: For a family of Filipino doctors, pandemic is personalWhile they toil to save the lives of coronavirus patients, physicians face private struggles, too.
Read more »
Gilead says remdesivir helped moderate COVID-19 patients improveGilead Sciences Inc said on Monday its antiviral drug remdesivir showed improvement in patients with moderate COVID-19 in a late-stage study.
Read more »